POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
Enacted

Governor Kim Reynolds signs Senate File 233 allowing eligible patients access to unapproved investigational…

Original title: A bill for an act relating to the right to try Act. (Formerly SF 56 .) Effective date: 07/01/2025.

Last action · May 19, 2025: Signed by Governor . S.J. 1051 .

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Does

Eligible patients with terminal, life-threatening, or severely debilitating illnesses are allowed to access unapproved investigational drugs, biological products, devices, and individualized treatments starting July 1, 2025. The legislation shields physicians from disciplinary actions and license revocation for recommending these treatments, protects patient heirs from inheriting related treatment debts, and prohibits state officials from blocking patient access.

Why it matters

Terminally or severely ill Iowa residents gain legal access to physician-recommended investigational drugs and personalized treatments that have cleared Phase 1 clinical trials but lack final federal approval, while assuming financial responsibility and exempting family members from resulting medical debt.

Background
  • Right to try laws are state-level statutes designed to allow terminally ill patients access to investigational drugs and medical devices that have not yet received final approval from the U.S. Food and Drug Administration. context
  • Senate File 233 was introduced during the 91st General Assembly of the Iowa General Assembly, building upon prior statutory provisions originally designated under Senate File 56. context

Who It Affects

Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.

Directly affected

Eligible patients

Patients with terminal or debilitating illnesses gain legal access to unapproved investigational treatments and personalized therapies with physician recommendation.

Directly affected

Treating physicians

Physicians are protected from state medical board and Medicare certification penalties when recommending investigational treatments to eligible patients.

Directly affected

Manufacturers and eligible facilities

Manufacturers and eligible facilities are permitted to provide investigational products to eligible patients for free or at cost, without facing private lawsuits if they act in good faith.

Directly affected

Patient heirs

Heirs are explicitly exempted from liability for outstanding treatment debts if a patient passes away while receiving an investigational product.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

Who qualifies as an eligible patient under the updated Right to Try Act?
An eligible patient is an individual who either has a terminal illness attested by a physician and has exhausted FDA-approved treatments, or has a life-threatening or severely debilitating illness and requires an based on their genetic profile, along with providing written informed consent.
Are health insurance companies required to cover the cost of investigational treatments?
No. The law specifies that health plans, third-party administrators, and governmental agencies are not required to provide coverage or pay costs associated with investigational drugs, biological products, devices, or individualized treatments.
Are a patient's heirs responsible for medical debts if the patient dies during treatment?
No. If a patient dies while being treated with an investigational product, the patient's heirs are not liable for any outstanding debt related to the treatment or lack of insurance, unless otherwise required by law.
Can a doctor be penalized by the state for recommending an investigational drug?
No. The Iowa Board of Medicine cannot take adverse action against a physician's license solely based on their recommendation of an investigational drug, biological product, device, or individualized treatment to an eligible patient.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Current status: Signed into law.

Procedural history

40 actions
  1. May 19, 2025SenateEnrolled
    Signed by Governor . S.J. 1051 .
  2. May 19, 2025Senate
    Reported correctly enrolled, signed by President and Speaker, and sent to Governor. S.J. 1050 .
  3. Apr 22, 2025House
    Message from Senate. H.J. 1015 .
  4. Apr 22, 2025Senate
    Immediate message. S.J. 852 .
  5. Apr 22, 2025SenateFloor
    Passed Senate , yeas 46, nays 0. S.J. 849 .
  6. Apr 22, 2025SenateFloor
    Senate concurred with S-3038 . S.J. 849 .
Show 34 earlier actions
  1. Mar 25, 2025House
    Explanations of votes. H.J. 812 .
  2. Mar 25, 2025House
    Explanation of vote. H.J. 811 .
  3. Mar 24, 2025House
    Message from House, with amendment S-3038 . S.J. 605 .
  4. Mar 21, 2025House
    Withdrawn. H.J. 772 .
  5. Mar 20, 2025House
    Withdrawn. H.J. 767 .
  6. Mar 20, 2025House
    SF 233 substituted. H.J. 758 .
  7. Mar 20, 2025HouseFloor
    Amendment H-1131 adopted. H.J. 758 .
  8. Mar 20, 2025House
    Immediate message. H.J. 767 .
  9. Mar 20, 2025HouseFloor
    Passed House , yeas 89, nays 0. H.J. 759 .
  10. Mar 20, 2025HouseFloor
    Amendment H-1132 adopted. H.J. 758 .
  11. Mar 20, 2025House
    Substituted for HF 802 . H.J. 758 .
  12. Mar 19, 2025House
    Amendment H-1131 filed. H.J. 752 .
  13. Mar 19, 2025House
    Amendment H-1132 filed. H.J. 752 .
  14. Mar 18, 2025House
    Placed on calendar under unfinished business. H.J. 682 .
  15. Mar 18, 2025HouseIntroduced
    Read first time, passed on file. H.J. 681 .
  16. Mar 18, 2025House
    Message from Senate. H.J. 680 .
  17. Mar 18, 2025Senate
    Immediate message. S.J. 559 .
  18. Mar 18, 2025SenateFloor
    Passed Senate , yeas 48, nays 0. S.J. 559 .
  19. Mar 5, 2025HouseIntroduced
    Introduced, placed on calendar. H.J. 521 .
  20. Mar 5, 2025Iowa Legislature
    Committee report approving bill, renumbered as HF 802 .
  21. Mar 3, 2025House
    Committee vote: Yeas, 14. Nays, 6. Excused, 1. H.J. 504 .
  22. Mar 3, 2025House
    Committee report, recommending amendment and passage. H.J. 3 .
  23. Feb 19, 2025Iowa Legislature
    Subcommittee recommends passage.
  24. Feb 17, 2025Iowa Legislature
    Subcommittee Meeting: 02/19/2025 12:30PM RM 19.
  25. Feb 17, 2025House
    Subcommittee: Barker, Baeth and Bradley. H.J. 340 .
  26. Feb 11, 2025HouseIntroduced
    Introduced, referred to Health and Human Services. H.J. 284 .
  27. Feb 10, 2025Senate
    Committee report approving bill, renumbered as SF 233 . S.J. 219 .
  28. Feb 10, 2025Senate
    Committee report, approving bill. S.J. 219 .
  29. Feb 10, 2025SenateIntroduced
    Introduced, placed on calendar. S.J. 214 .
  30. Jan 27, 2025Iowa Legislature
    Subcommittee recommends passage.
  31. Jan 23, 2025Senate
    Subcommittee Meeting: 01/27/2025 1:30PM Senate Lounge.
  32. Jan 22, 2025Senate
    Subcommittee reassigned: Alons, Celsi, and Klimesh. S.J. 126 .
  33. Jan 21, 2025Senate
    Subcommittee: Rowley, Campbell, and Celsi. S.J. 114 .
  34. Jan 16, 2025SenateIntroduced
    Introduced, referred to Health and Human Services. S.J. 104 .

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift95% confidence

Expansion of Right to Try to Individualized Treatments

The updated act specifically broadens statutory definitions to include customized genetic treatments like gene therapy and neoantigen vaccines alongside traditional investigational drugs.

Connected Entities

Paul Pate, United States food and drug administration, Kim Reynolds and 3 more
PersonPaul Pate“Secretary of State of Iowa”Map →
OrganizationUnited States food and drug administration“Federal agency overseeing drug and device approvals”Map →
PersonKim Reynolds“Governor of Iowa who approved Senate File 233”Map →
PersonCharles Smithson“Secretary of the Senate”Map →
PersonAmy Sinclair“President of the Senate”Map →
PersonPat Grassley“Speaker of the House”Map →

Sources

Open source document

www.legis.iowa.gov

Analysis Score

0–100
  • Significance65
    How much this matters to a regular citizen
  • Controversy25
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz20
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record